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DDX3 is a human RNA helicase that is involved in RNA processing and
important human diseases. This enzyme belongs to the DEAD-box protein
family, the members of which are characterized by the presence of nine
conserved motifs including the Asp-Glu-Ala-Asp motif that defines the family.
DDX3 has two distinct domains: an ATP-binding domain in the central region of
the protein and a helicase domain in the carboxy-terminal region. The helicase
domain of DDX3 was cloned and overexpressed in Escherichia coli. Crystal-
lization experiments yielded crystals that were suitable for X-ray diffraction
analysis. The final crystallization conditions were a reservoir solution consisting
of 2M ammonium sulfate, 0.1M imidazole pH 6.4 plus 5 mM spermine
tetrahydrochloride and a protein solution containing 10 mM HEPES, 500 mM
ammonium sulfate pH 8.0. The crystals of the helicase domain belong to the
monoclinic space group P21, with unit-cell parameters a = 43.85, b = 60.72,
c = 88.39 A˚,  =  = 90,  = 101.02, and contained three molecules per
asymmetric unit. These crystals diffracted to a resolution limit of 2.2 A˚ using
synchrotron radiation at the European Synchrotron Radiation Facility (ESRF)
and the Swiss Light Source (SLS).
1. Introduction
Higher order RNA structures are formed by intramolecular and
intermolecular base pairs that are functionally important. RNA
helicases regulate practically all processes in which RNA manipula-
tion is involved, from transcription and translation to nuclear export
and RNA degradation (Cruz et al., 1999). They catalyze the modifi-
cation of higher order RNA structures, such as secondary-structure
melting, strand separation and RNA–protein dissociation (Schwer,
2001). Thus, helicases are among the most numerous proteins, with
representative members in all three kingdoms of life (Cruz et al.,
1999). Even though they are not essential in all cases, they do play a
very important role in general RNA metabolism (Rocak & Linder,
2004).
DDX3, also called CAP-Rf (You et al., 1999) or DBX (Lahn &
Page, 1997), is a DEAD-box protein of 74 kDa whose precise func-
tions inside the cell are not completely understood. DDX3 bears all
nine motifs of the DEAD-box protein family including the char-
acteristic Asp-Glu-Ala-Asp (DEAD box). It has two distinct regions
that contain all the conserved motifs. The first region contains the
Q-motif (amino acids 178–206; Cordin et al., 2004) and an ATP-
binding and hydrolysis domain (amino acids 209–401). This includes
motifs I and II (Walker A and B, respectively), Ia, Ib and the motif III
that links the ATP binding and hydrolysis to the conformational
changes required for helicase activity. The second region consists of
the helicase domain (amino acids 412–573) and comprises motifs IV
and V. These motifs are probably involved in RNA binding together
with motifs Ia and Ib from the first region. Also present in the second
region is motif VI, which is believed to participate in ATP binding
(Rocak & Linder, 2004). Moreover, the helicase activity of DDX3 has
been shown to be dependent on ATP hydrolysis and vice versa
(Yedavalli et al., 2004).
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This enzyme is involved in diverse processes such as mRNA spli-
cing by co-localizing with splicing factors (Zhou et al., 2002) and
mRNA transport, as it is present in RNA-transporting granules
(Kanai et al., 2004). More recently, it has also been described as a
tumour suppressor through up-regulation of p21waf1/cip1 (Chao et
al., 2006). In addition to its possible implication in proliferation
processes, DDX3 is directly involved in other important human
diseases that affect large percentages of the world population. This is
the case in AIDS, in which DDX3 is upregulated (Krishnan &
Zeichner, 2004) and is required for HIV-1 Rev-RRE export from the
nucleus (Yedavalli et al., 2004). In hepatitis C, DDX3 is down-
regulated (Chang et al., 2006) through a direct interaction with the
HCV (hepatitis C virus) core protein during infection, suppressing its
RNA-unwinding activity (Owsianka & Patel, 1999; Mamiya &
Worman, 1999; You et al., 1999).
Although the structures of other RNA helicases and/or their
domains have been solved (Sengoku et al., 2005; Caruthers et al., 2000;
Story et al., 2001), there is scant structural information on human
RNA helicases and none is available for DDX3. Even though the
helicase domain is supposed to be well conserved among the different
DEAD-box proteins, an accurate molecular description would be
very useful in order to fully understand the molecular mechanisms of
RNAunwinding and the interactions of DDX3 with other molecules.
Moreover, the fact that DDX3 is involved in different processes
during the development of HIV and HCV viral infections and the
possibility that this RNA helicase could function as a tumour
suppressor reveal it to be a key regulator of important RNA
processes. These crucial roles in RNA metabolism suggest it as a
possible drug target in these diseases.
2. Materials and methods
2.1. Protein expression and purification
The cDNA sequence corresponding to residues 407–578 of human
DDX3 (DDX3hel) was amplified by PCR and cloned into a pCold
vector (Takara) using NdeI and BamHI restriction sites. A 6His tag
followed by a tobacco etch virus (TEV) protease cleavage site were
introduced at the 50 site. Escherichia coli BL21 (DE3) cells were
transformed with the pColdIII-DDX3hel vector. Cell cultures were
grown at 310 K and induced with 1 mM IPTG when the OD reached
0.5–0.8. The temperature was then reduced to 288 K and the cultures
were grown overnight. Cells were collected the next morning and the
pellets were frozen at 193 K. Upon thawing, a pellet corresponding to
4 l culture was resuspended in 50 mM Tris, 500 mM ammonium
sulfate pH 8.0 (buffer A). Cells were disrupted by sonication at 278 K
and cell debris was removed by centrifugation. The protein was
purified using a 5 ml His-Trap affinity column (Amersham Bios-
ciences). The column was washed with buffer A and the protein was
eluted with an imidazole step gradient. The eluted DDX3hel was then
subjected to proteolytic cleavage with TEV protease at 278 K over-
night to remove the 6His tag. The mixture was again loaded onto a
5 ml His-Trap affinity column (Amersham Biosciences) and the
untagged protein eluted in the flowthrough. The sample was collected
and loaded onto a gel-filtration column (Superdex 75, Amersham
Biosciences) previously equilibrated with 10 mM HEPES, 500 mM
ammonium sulfate pH 8.0. The protein was concentrated to
10 mg ml1 using an ultrafiltration cell (Amicon), flash-frozen in
liquid nitrogen and stored at 193 K. The protein purity was analyzed
by running a 10% SDS–PAGE gel (Fig. 1a) and protein homogeneity
was evaluated using dynamic light scattering and mass spectrometry
(data not shown). Circular-dichroism spectra and thermal denatura-
tion showed that the protein conserved its secondary and tertiary
structure before and after freezing (data not shown). The protein
concentration was determined by the Bradford assay (Bradford,
1976; Bio-Rad) using BSA as a standard.
2.2. Crystallization
Crystallization screenings were performed with a Cartesian robot
(Genomic Solutions) using the sitting-drop method with nanodrops
of 0.1 ml protein solution plus 0.1 ml reservoir solution and a reservoir
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Figure 1
Purification and crystallization of the human DDX3 helicase domain. (a) SDS–PAGE of purified and concentrated DDX3hel. Left lane, molecular-weight markers (kDa). (b)
Initial spherulites of DDX3hel. (c) Monoclinic crystals of DDX3hel obtained from the initial spherulites (see text for details). Crystals of human DDX3hel behaved well in the
cryo-buffer conditions described in the text and diffracted to 2.2 A˚. The pictures were taken at different magnification settings.
volume of 70 ml. Initially, small spherulites (Fig. 1b) were obtained
after 48 h in 0.1M HEPES pH 7.5, 2.5M ammonium sulfate
(condition No. 10 from the MbClass II suite screen; Nextal-Qiagen)
at 289 K. Refinement of the crystallization conditions was performed
at the same temperature using the hanging-drop method in Linbro
plates. The reservoir volume was 500 ml and drops were 1 + 1 ml. After
several rounds of optimization with different concentrations of
precipitant, pH variations and the Additive Screen from Hampton
Research, crystals appeared in 2M ammonium sulfate, 0.1M
imidazole pH 6.4 plus 5 mM spermine tetrahydrochloride in 2 ml
drops. Spermine was not critical for crystal formation, but the best
data sets were obtained from crystals grown under these conditions.
Although many crystals grew in the drop, these specimens could be
mounted in a cryoloop. The quality and size (average dimensions
0.2  0.01  0.01 mm) of the crystals were suitable for diffraction
experiments (Fig. 1c).
2.3. Data collection and reduction
The DDX3hel crystals were cryoprotected using a buffer consisting
of 2M ammonium sulfate, 0.1M imidazole pH 6.4 and 20% glycerol.
Crystals were transferred from the original drop to the cryoprotec-
tant drop, incubated for 5 s and then flash-cooled in liquid nitrogen.
Although several data sets were obtained in-house using an FR-591
Bruker generator, the crystals only diffracted to 3.8 A˚. Therefore, the
remainder of the data sets of DDX3hel were collected using
synchrotron radiation at the ID14-1 and the PX beamlines at the
ESRF (Grenoble) and the SLS (Villigen), respectively. The diffrac-
tion data in Table 1 were recorded on an ADSC Q210 detector at
ID14-1. The best data set was collected using ’ = 1 and a wave-
length of 0.9 A˚. Processing and scaling were accomplished with
HKL-2000 (Otwinowski & Minor, 1997); the statistics of the crys-
tallographic data are summarized in Table 1.
3. Results and discussion
The recombinant DDX3 helicase domain (amino acids 407–578;
DDX3hel) has a molecular weight of 20 kDa. Attempts to purify the
full-length protein as well as constructs larger than DDX3hel were
initially conducted, but solubility problems led us to try this construct
instead. DDX3hel was expressed in E. coli with a 6His tag at the
N-terminus, with typical yields of 75 mg pure protein per litre of
culture. The recombinant protein was subjected to His-tag affinity
purification and the His tag was subsequently removed using TEV
protease. The TEV protease was separated from the DDX3hel frag-
ment using another round of His-trap affinity chromatography and a
gel-filtration purification step. The purified DDX3hel was concen-
trated and used for crystallization assays. Although initial hits were
just spherulites without crystalline form (Fig. 1b), several rounds of
refinement allowed us to produce small needles. After optimization,
crystals that were suitable in size and quality for diffraction experi-
ments were obtained (Fig. 1c). Crystallization reproducibility was
very high since only one batch of protein was used for the entire
screening and optimization of the crystallization conditions.
The crystals were tested using a synchrotron-radiation source in
order to obtain higher resolution data. Several native data sets were
collected at 100 K on beamline ID14-1 and the PX beamline at the
ESRF (Grenoble) and the SLS (Villigen), respectively. Using
synchrotron radiation on these undulator-equipped beamlines, the
crystals diffracted to 2.2 A˚ (Fig. 2). The statistics for a data set are
given in Table 1.
The crystals belong to the monoclinic space group P21, with unit-
cell parameters a = 43.85, b= 60.72, c= 88.39 A˚, =  = 90, = 101.02.
The Matthews coefficient and the self-rotation function (not shown)
suggested the presence of three protein molecules per asymmetric
unit (VM = 1.96 A˚
3 Da1) and a solvent content of 37.13%. The
collected diffraction data were 99% complete with a multiplicity of
5.9 and an overall I/(I) of 6.2 (see Table 1 for details). One possi-
bility for solution of the structure of DDX3hel is to use the molecular-
replacement method, taking advantage of the previously described
structures of Vasa (PDB code 2db3) from Drosophila melanogaster,
eIF4A (PDB code 1fuk) from Saccharomyces cerevisiae and
MjDEAD (PDB code 1hv8) from Methanococcus jannaschii, all of
which are related to DDX3. In case of difficulties, heavy-atom deri-
vatization or selenomethionine-derived protein could be produced to
solve the structure using multiple isomorphous replacement (MIR)
or multiple anomalous dispersion (MAD) experiments.
These are the first crystals reported of DDX3 RNA helicase. We
believe that these studies will help to elucidate the molecular
mechanisms of RNAunwinding and the important interactions of this
enzyme with different proteins and RNA in the cell. Moreover, owing
to the involvement of DDX3 in severe diseases such as AIDS,
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Table 1
Data-collection statistics of human DDX3 helicase domain.
Resolution
limits (A˚) hI/(I)i
Completeness
(%) Multiplicity
Observed
reflections
Unique
reflections Rsym†
50.0–6.96 12.9 98.7 6.1 4712 776 0.042
6.95–4.92 11.1 99.2 7.2 9940 1363 0.055
4.91–4.02 10.6 99.4 7.5 13064 1752 0.057
4.01–3.48 8.7 99.4 7.5 15700 2081 0.073
3.47–3.11 6.0 99.4 7.6 17520 2314 0.110
3.10–2.84 3.5 99.3 6.8 17674 2582 0.177
2.83–2.63 2.4 99.3 5.6 15483 2784 0.244
2.62–2.46 1.8 99.2 4.8 14381 2968 0.294
2.45–2.32 1.5 99.1 4.3 13597 3133 0.356
2.31–2.20 1.6 99.0 4.0 13254 3331 0.388
Overall 6.2 99.0 5.9 135325 23084 0.091
† Rsym =
P
h
P
i jIh;i  hIhij=
P
h
P
i jIh;ij.
Figure 2
Diffraction pattern from the native crystals using synchrotron radiation at ID14-1
at the ESRF. Circles are labelled with the resolution limits in A˚.
hepatitis C and cancer, high-resolution structural information on
DDX3 could help in the design of drugs in the search for new
therapies.
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